PTPN9表达水平与结直肠癌的临床关系研究

doi:10.11904/j.issn.1002-3070.2019.05.006

摘要/Abstract

摘要： 目的探究PTPN9在结直肠癌中的表达情况及其与各项临床指标关系。方法回顾性分析2007年12月—2008年12月于哈医大附属肿瘤医院就诊且病理明确、临床资料完整的结直肠癌患者,共146例。随机挑选出132例患者的肿瘤组织和14例患者的非癌组织,进行PTPN9蛋白质免疫组化染色,由两位高年资的病理科医师进行双盲评分。参照染色评分,比较患者的年龄、性别、大体形态、分化程度、预后等各项临床指标。生存分析采用Kaplan-Meier曲线,应用Cox比例风险模型进行多因素分析。结果 PTPN9在肿瘤组织中呈高表达水平(P=0.009),且与N分期(P=0.021)、M分期(P=0.022)、病理分期(P=0.008)、糖尿病患病(P=0.022)和生存情况(P=0.001)有关。与低表达PTPN9的结直肠癌患者相比,高表达PTPN9的结直肠癌患者总生存期下降(P＜0.001)。多因素Cox回归分析显示,PTPN9的表达水平为影响结直肠癌患者预后的独立风险因素之一(HR=1.202,P＜0.05)。结论 PTPN9的表达强度在癌组织与非癌组织中有统计学差异,在癌组织中的表达强度更高;随着PTPN9的表达强度增高,肿瘤病理分期也随之升高;高表达的PTPN9与糖尿病发病之间存在一定相关性;高表达PTPN9的结直肠癌患者的总生存期较短。

关键词: 结直肠癌, PTPN9, 肿瘤病理分期, 预后

Abstract: Objective The aim of this study was to investigate the expression of PTPN9 in colorectal cancer and its relationship with various clinical indicators.Methods A retrospective study of 146 patients with colorectal cancer who had a clear pathology and complete clinical data from December 2007 to December 2008 at Harbin Medical University Cancer Hospital was performed.Tumor tissues from 132 patients and non-cancerous tissues from 14 patients were randomly selected for determination of PTPN9 protein by immunohistochemistry,and double-blind scores were performed by two senior pathologists.According to the staining score,the clinical indicators such as age,gender,gross morphology,degree of differentiation and prognosis were compared.Survival analysis was performed by Kaplan-Meier curve using Cox proportional hazard model for multivariate analysis.Results The expression of PTPN9 in tumor tissues was statistically different from non-tumor tissues(P=0.009).There was a relationship between PTPN9 expression and N stage(P=0.021),M stage(P=0.022),pathological stage(P=0.008),clinical indicators such as diabetes(P=0.022)and survival(P=0.001).High expression of PTPN9 would result in a decrease overall survival in patients with colorectal cancer(P＜0.001).Multivariate Cox regression analysis showed that the expression of PTPN9 was one of the independent risk factors affecting the prognosis of patients with colorectal cancer(HR=1.202,P＜0.05).Conclusion The expression of PTPN9 is significantly different between cancer tissues and non-cancerous tissues,and the expression of PTPN9 is higher in cancer tissues.As the expression of PTPN9 was increased,the pathological stage of tumors was also increased.The high expression of PTPN9 is a correlation with the onset of diabetes and also leads to a decrease in overall survival of patients with colorectal cancer.

Key words: Colorectal, PTPN9, Tumor stage, Prognosis

中图分类号:

R735.3+5

夏天一, 张博淼, 姚克非, 崔滨滨. PTPN9表达水平与结直肠癌的临床关系研究[J]. 实用肿瘤学杂志, 2019, 33(5): 415-419.

XIA Tianyi, ZHANG Bomiao, YAO Kefei, CUI Binbin. Clinical relationship between PTPN9 expression and colorectal cancer[J]. Journal of Practical Oncology, 2019, 33(5): 415-419.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2019.05.006

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2019/V33/I5/415

参考文献

1 Torre LA,Bray F,Siegel RL,et al.Global cancer statistic,2012[J].CA Cancer J Clin,2015,65(2):87-108.
2 Hunter T.Signaling-2000 and beyond[J].Cell,2000,100(1):113-127.
3 Sato Y,Arai H,Miyata A,et al.Primary structure of alpha-tocopherol transfer protein from rat liver.Homology with cellular retinaldehyde-binding protein[J].J Biol Chem,1993,268(24):17705-17710.
4 Zhu J,Li H,Ma J,et al.PTPN9 promotes cell proliferation and invasion in Eca109 cells and is negatively regulated by microRNA-126[J].Oncol Lett,2017,14(2):1419-1426.
5 Hu B,Yan X,Liu F,et al.Downregulated expression of PTPN9 contributes to human hepatocellular carcinoma growth and progression[J].Pathol Oncol Res,2016,22(3):555-565.
6 Hong Y,Liang H,Uzair-Ur-Rehman,et al.miR-96 promotes cell proliferation,migration and invasion by targeting PTPN9 in breast cancer[J].Sci Rep,2016,6:37421.
7 Sun T,Aceto N,Meerbrey KL,et al.Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase[J].Cell,2011,144(5):703-718.
8 Su F,Ren F,Rong Y,et al.Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer[J].Breast Cancer Res,2012,14(2):38.
9 Gong W,Wang L,Yao JC,et al.Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer[J].Clin Cancer Res,2005,11(4):1386-1393.
10 Niu G,Wright KL,Huang M,et al.Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis[J].Oncogene,2002,21(13):2000-2008.
11 Hao Q,Samten B,Ji HL,et al.Tyrosine phosphatase PTP-MEG2 negatively regulates vascular endothelial growth factor receptor signaling and function in endothelial cells[J].Am J Physiol Cell Physiol,2012,303(5):C548-553.
12 Chatterjee S,Heukamp LC,Siobal M,et al.Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer[J].J Clin Invest,2013,123(4):1732-1740.
13 Charles C,Koo S,Wang Y,et al.Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling[J].Cell Metab,2006,3(5):367-378.
14 Mashili F,Chibalin AV,Krook A,et al.Constitutive STAT3 phosphorylation contributes to skeletal muscle insulin resistance in type 2 diabetes[J].Diabetes,2013,62(2):457-465.

[1]	刘四卫, 崔玥, 孙元元, 胡晶, 张文睿, 曹孟儒. FOXD3在肺癌细胞中的作用[J]. 实用肿瘤学杂志, 2019, 33(5): 390-396.
[2]	徐亭, 严斐斐, 张纯慧, 张艳桥. 胃癌骨转移患者临床病理与预后分析[J]. 实用肿瘤学杂志, 2019, 33(5): 436-441.
[3]	李思维 , 庞达. 长链非编码RNA(lncRNA)在癌症中的作用[J]. 实用肿瘤学杂志, 2019, 33(5): 471-475.
[4]	曲雁飞, 刘超, 王勃军, 方琳, 张艳桥. CSN6基因在肝细胞癌组织中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(4): 328-333.
[5]	刘金涛, 高玲, 周会会. MAGEA4和EB1蛋白在肺癌组织中的表达及其与临床病理特征及预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(4): 334-339.
[6]	方瑄, 陈洪生, 李国东刘明. 异常隐窝灶治疗的研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 376-379.
[7]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[8]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[9]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[10]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[11]	方琳, 刘超, 张纯慧, 张艳桥. 转移性结直肠癌维持治疗的研究现状与治疗策略[J]. 实用肿瘤学杂志, 2019, 33(2): 173-178.
[12]	佟广海, 田洋, 吴华星. 脂质组学在结直肠癌研究中的应用[J]. 实用肿瘤学杂志, 2019, 33(2): 179-192.
[13]	卢姣云, 张清媛. 实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 183-187.
[14]	刘恒辰, 张新宇. Toll样受体信号通路作为结直肠癌潜在治疗靶点的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 188-192.
[15]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.